Why the study?
With the increasing use of GLP-1 receptor agonists and dual GIP/GLP-1 agonists for obesity and type 2 diabetes, understanding their real-world effectiveness and safety is essential.
Does tirzepatide reduce MACE and all-cause mortality compared to semaglutide in patients with obesity and type 2 diabetes?
Does tirzepatide reduce MACE and all-cause mortality compared to semaglutide in patients with obesity and type 2 diabetes?
In a real-world cohort of patients with obesity and type 2 diabetes, tirzepatide was associated with lower risks of MACE, all-cause mortality, and better glycemic control compared to semaglutide over 1 year.
No takes yet. Share an insight, caveat, or question.
Observational tirzepatide–semaglutide comparison in obese T2D should not yet change practice; leaves open questions on real-world effectiveness.
Qadeer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: